Showing results (421-430 of 483) with videos related to
Sort By:
Pageof 49
Investigative Radiology|October 18, 2022
Deep Learning for Automatic Bone Marrow Apparent Diffusion Coefficient Measurements From Whole-Body Magnetic Resonance Imaging in Patients With Multiple Myeloma: A Retrospective Multicenter StudyMarkus Wennmann, Peter Neher, Nikolas Stanczyk, et al.Scientific Reports|October 10, 2025
Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myelomaFabian Bauer, Marina Hajiyianni, Niels Weinhold, et al.Journal of Hepatology|March 9, 2016
Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER studyMichael Bitzer, Marius Horger, Edoardo G Giannini, et al.The Lancet. Haematology|January 5, 2025
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trialRoberto Mina, Anne K Mylin, Hisayuki Yokoyama, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2020
Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA TrialAurore Perrot, Thierry Facon, Torben Plesner, et al.BMC Cancer|May 30, 2019
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myelomaHans Salwender, Uta Bertsch, Katja Weisel, et al.The New England Journal of Medicine|May 11, 2012
Continuous lenalidomide treatment for newly diagnosed multiple myelomaAntonio Palumbo, Roman Hajek, Michel Delforge, et al.Advances in Therapy|May 12, 2025
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect ComparisonNoemi Puig, Joris Diels, Suzy van Sanden, et al.Annals of Hematology|May 10, 2021
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the USFaith Davies, Robert Rifkin, Caitlin Costello, et al.Leukemia & Lymphoma|April 10, 2020
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myelomaKatja Weisel, Meletios Dimopoulos, Philippe Moreau, et al.Pageof 49